secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001654954-25-002385
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax raises $25M, expands Phase 3 LEVEL study to 230 patients, adds LEVEL-2 trial
--------------------------------------------------------------------------------

- Private placement with RTW Investments grossed ~$25M; issued 378K shares + pre-funded warrants for 3.76M shares at $6.04/$6.03.
- FDA accepted amendment to expand LEVEL study from 152 to 230 patients, increasing statistical power to >95%; enrollment expected by end of 2025.
- FDA agreed to initiate second global Phase 3 LEVEL-2 study; first patient expected in 2025; primary endpoint 6MWD at 26 weeks.
- Blinded LEVEL data shows >95% patients remain on therapy, no safety signals; topline data expected mid-2026.
- Proceeds extend cash runway through end of 2027, funding Phase 3 trials and operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495425002385/0001654954-25-002385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495425002385/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-002385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer